Emend

Product manufactured by Merck Sharp & Dohme Corp.

Application Nr Approved Date Route Status External Links
NDA022023 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Emend ® For Injection, In Combination With Other Antiemetic Agents, Is Indicated In Adults And Pediatric Patients 6 Months Of Age And Older For The Prevention Of: Acute And Delayed Nausea And Vomiting Associated With Initial And Repeat Courses Of Highly Emetogenic Cancer Chemotherapy (hec) Including High-Dose Cisplatin. Delayed Nausea And Vomiting Associated With Initial And Repeat Courses Of Moderately Emetogenic Cancer Chemotherapy (mec). Emend ® For Injection Is A Substance P/neurokinin-1 (nk 1 ) Receptor Antagonist, Indicated In Adults And Pediatric Patients 6 Months Of Age And Older, In Combination With Other Antiemetic Agents, For The Prevention Of ( 1 ): Acute And Delayed Nausea And Vomiting Associated With Initial And Repeat Courses Of Highly Emetogenic Cancer Chemotherapy (hec) Including High-Dose Cisplatin. Delayed Nausea And Vomiting Associated With Initial And Repeat Courses Of Moderately Emetogenic Cancer Chemotherapy (mec). Limitations Of Use ( 1 ) Emend Has Not Been Studied For Treatment Of Established Nausea And Vomiting. Limitations Of Use Emend Has Not Been Studied For The Treatment Of Established Nausea And Vomiting.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Fosaprepitant Dimeglumine FOSAPREPITANT DIMEGLUMINE ZINC3939013

Comments